MENU

September 20, 2022

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer

–6th approved indication of toripalimab in China, bringing more treatment options to patients with advanced NSCLC SHANGHAI, China, Sept. 20, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company

Read More ➜

Recent News

ADVERTISMENT